COLLIE, Western Australia and NEW YORK – Cannaponics Limited “Cannaponics”, a licensed medicinal cannabis cultivation, manufacturing and research company, announced a licensing partnership with New Age Nanotech, a provider of the clinically-backed drug delivery technology for cannabinoids, called Solutech™.
According to the terms of the agreement, the license allows for product development and commercialization of both pharmaceutical and consumer products, including API, final dose forms such as medicines and clinical trial products, complimentary medicines, cosmeceuticals, food supplements, nutraceuticals, and oral solutions. Potential future product developments may include liquid shots, and ready-to-drink beverages containing cannabis derived THC and/or CBD. Cannaponics shall have exclusive rights for Australia and non-exclusive rights for certain countries in South East Asia and Europe, as well as Israel and Brazil.
“Our vision at Cannaponics is establishing a carbon-neutral pharmaceutical facility to grow high quality cannabis crops and develop effective plant-based pharmaceuticals. Our partnership with New Age Nanotech’s cutting-edge Solutech™ will allow us to build on successful Phase 1 clinical trials and demonstrate clinical efficacy for proprietary treatments for patients in need. Our Solutech™ based treatment range will complement our traditional medicinal cannabis formulations and may allow future expansion into the nutraceutical and beverage sectors as regulations allow,” said Rod Zakostelsky, Founder and Managing Director of Cannaponics.
Cannaponics, at its sole cost and expense, will be responsible for development and commercialization of the cannabis products and will have the right to manufacture the licensed products in Australia. Under the terms of the agreement, Cannaponics will maintain exclusivity of the license in Australia based on certain commercial metrics.
New Age Nanotech is an expert in oral delivery technologies, and offers Solutech™ – a clear, pharmaceutical-grade, bioactive formulation to the cannabis and pharmaceutical industries.
“We are excited to enter into this partnership together with Cannaponics, who shares our strategic vision to provide unique, high quality, clinical evidence-based cannabis products to patients and their potential future adult-use consumers.”
New Age Nanotech’s early research on Solutech™ showed dramatically increased speed of absorption and elimination (fast onset and offset of effects) and peak blood levels, along with a consistent and desirable consumer experience. Most notably, Solutech™ was evaluated successfully in a pivotal Health Canada Phase I human clinical trial led by KGK Science, a premier clinical research organization. All subjects who were administered Solutech™ experienced an onset of effects within minutes, with the full onset occurring after 20 minutes. After about 2.5 hours post-dose, the effects diminished consistently, as well. A predictable onset and offset may allow for a better experience with cannabis as well as an ability to re-dose effectively, if desired.
(This information is primarily sourced from Cannaponics. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).